1.Analysis of the Drug Monitoring Information by Using the CYP-Database for Predicting Drug-Drug Interactions
Katsunori Yamaura ; Maki Shimada ; Noriyuki Nakayama ; Masanori Ogawa ; Tadashi Nomoto ; Eiji Nakano ; Takao Namiki ; Koichi Ueno
Japanese Journal of Drug Informatics 2011;12(3):111-116
Objective: In the previous study, the CYP database was constructed in order to relate drug-drug interactions to the CYP metabolic information of the package inserts. In this study, we evaluated the clinical usefulness of the CYP database by using the Pharmaceutical and Medical Devices Agency (PMDA) Drug Monitoring Information.
Methods: We examined the drugs in CYP isoform responsible for drug metabolism. The age, sex, suspect drugs and co-administered drugs were extracted from 6,236 cases of the PMDA database of drug monitoring from January till November of 2008.
Results: Twenty-three percent of all cases had co-administered drugs. Forty-five percent of these cases were metabolized both suspect and co-administered drugs by the same CYP isoform, and three fourths of these cases were able to be detected only by the CYP database. In addition, the administration of substrate medicines in combination with substrate medicines was the largest (57%), followed by cases of substrate medicines in combination with inhibitor medicines (28%). Seventy-seven percent of the suspect drugs that had a large number of reported cases of side effects were substrate medicines, and the frequency of co-administration with substrate medicines was very high.
Conclusion: These data suggest that the CYP database, being used together with package inserts, might be a clinically useful tool to avoid adverse events caused by drug-drug interactions.
2.9-4 Education Given at Jichi Medical University's Dormitory during the COVID-19 Pandemic: Strategies and Challenges in a Boarding Medical College
Yosikazu NAKAMURA ; Yoshihiro ITAI ; Nobuko MAKINO ; Masaaki SATO ; Shigeo NAGASHIMA ; Yukiko ISHIKAWA ; Kenji KUROIWA ; Teppei SASAHARA ; Yasuko NODA ; Masami MATSUMURA ; Shizukiyo ISHIKAWA ; Masanori OGAWA ; Akinori YAMABE ; Yoshikazu ASADA
Medical Education 2020;51(3):306-307
3.International comparison of criteria for evaluating sensitization of PRTR-designated chemical substances.
Tomoe MURAKAMI ; Tsunehiro OYAMA ; Toyohi ISSE ; Masanori OGAWA ; Takuya SUGIE ; Toshihiro KAWAMOTO
Environmental Health and Preventive Medicine 2007;12(2):56-65
In this study, we aim to compare the criteria for sensitizers among national organizations in various countries and international organizations, and to specify whether each Pollutant Release and Transfer Register (PRTR)-designated chemical substance is a sensitizer by each organization. The definition of sensitizing chemicals and the designation of respective sensitizers according to the PRTR law, Japan Society for Occupational Health (JSOH), American Conference of Governmental Industrial Hygienists (ACGIH), European Union (EU), and Deutsche Forschungsgemeinshaft (DFG) were studied. Of the 435 PRTR-designated chemical substances, 15 are listed as sensitizers according to the PRTR law, 16 as sensitizers of the airway and 21 as sensitizers of the skin by JSOH, 12 as sensitizers (no discrimination) by ACGIH, 19 (airway) and 85 (skin) by EU, and 15 (airway) and 43 (skin) by DFG. Only 9 substances were designated as sensitizers by all these organizations. The variation in the designation of sensitizers is accounted for by the differences in the classification criteria and grouping of chemical substances. JSOH limits the definition of sensitizers to substances that induce allergic reactions in humans and uses only human data. Other organizations utilize not only human evidence but also appropriate animal tests. In addition, EU designates an isocyanate as a sensitizer except those for which there is evidence showing that they do not cause respiratory sensitivity. The worldwide enforcement of the globally harmonized system (GHS) of classification and labeling of chemicals could promote not only the consistent designation of sensitizers among national and international organizations, but also the development of testing guidelines and classification criteria for mixtures.
4.Evidence-based prevention (EBP): A review of cytochrome P450 expression in the bronchial epithelium and new approach to lung cancer prevention.
Tsunehiro OYAMA ; Toyohi ISSE ; Tomoe MURAKAMI ; Rie SUZUKI-NARAI ; Masanori OGAWA ; Tetsunosuke YAMAGUCHI ; Tsuyoshi KINAGA ; Yasunori YASHIMA ; Shinichi OZAKI ; Yong-Dae KIM ; Heon KIM ; Toshihiro KAWAMOTO
Environmental Health and Preventive Medicine 2006;11(3):97-101
The number of fatalities in Japan attributable to lung cancer exceeded 50000 in 2001. It is socially desirable that various markers, which can be utilized for the prevention of lung cancer, be established. We believe that smoking or exposure to carcinogens in air induces mutations in bronchial and alveolar epithelia, leading to the development of lung cancer. It would be useful to have markers of individual differences in susceptibility to chemical carcinogen-induced lung cancer 1) to identify genetic polymorphisms of enzymes metabolizing chemical carcinogens and 2) to investigate the expression of enzymes metabolizing chemical carcinogens. In this paper, we review CYP expression in the bronchial epithelium. CYP1, CYP2 and CYP3 are expressed in the bronchial epithelium. We also show the relationship between the genetic polymorphisms of cytochrome P450 (CYP) and a person's susceptibility to chemical carcinogen-induced lung cancer. We demonstrate the relationship between cigarette consumption and the CYP expression profile in the bronchial epithelium. To maintain and promote public health, we must apply evidence, such as CYP polymorphisms and CYP profiles to disease prevention and also to aggressively advance evidence-based prevention (EBP) of lung cancer.
5.Correction to: Comparison of hepatitis B vaccine efficacy in Japanese students: a retrospective study.
Masanori OGAWA ; Dai AKINE ; Teppei SASAHARA
Environmental Health and Preventive Medicine 2020;25(1):5-5
Following publication of the original article [1], the authors spotted errors in their paper concerning the positive rate in the right side in Table 2.
6.Comparison of hepatitis B vaccine efficacy in Japanese students: a retrospective study.
Masanori OGAWA ; Dai AKINE ; Teppei SASAHARA
Environmental Health and Preventive Medicine 2019;24(1):80-80
BACKGROUND:
Two types of recombinant hepatitis B virus (HBV) vaccines are available in Japan. One type uses the antigen from genotype A (Heptavax-II®) and the other uses the antigen from genotype C (Bimmugen®). Potential differences in productivity of the hepatitis B virus surface (HBs) antibody between vaccines have not been studied in detail. We investigated the acquired level of immunity against HBV in association with two vaccines, their administration routes, and patient sex. We present the appropriate inoculation method based on the characteristics of each vaccine.
METHODS:
Data of 1135 medical and nursing students (481 men and 651 women) were used, each of whom was unvaccinated prior to recruitment and subsequently vaccinated three times prior to the study. The vaccine type and administration route differed according to the university department and enrolling year. The students were categorized into the following three groups: Bimmugen®-subcutaneous group, Heptavax-II®-subcutaneous group, and Heptavax-II®-intramuscular group. The total and sex-segregated positive rates of the HBs antibody among the three groups were compared using Pearson's chi-square test. The effect of time between the HBs antibody test and vaccine administration on the HBs antibody level was also analyzed similarly.
RESULTS:
The Bimmugen®-subcutaneous group showed the highest positive HBs antibody rate (92.0%) among the three groups. In the Heptavax-II® group, the positive rate was 66.3% in the subcutaneous injection group and 89.1% in the intramuscular injection group. There was a significant difference among these three groups. In terms of sex, women showed a significantly higher average positive rate than men in each group. In terms of effect of time between the HBs antibody test and vaccine administration, no significant differences were observed.
CONCLUSIONS
Bimmugen® is associated with more effective HBs antibody production than Heptavax-II® in Japanese students. However, the Heptavax-II® vaccine is an appropriate choice for HBV vaccination in areas where HB is caused predominantly by HBV genotype C. With both vaccines, women tended to acquire more immunogenicity than men. Intramuscular injection may be the preferred administration route due to the possibility of local reactions.